Efficacy and Safety of Weight-based Dosing of Daptomycin in Obese Patients: A Systematic Review
Main Article Content
Keywords
Antibiotic, Obesity, Drug safety, Adverse drug effects
Abstract
Purpose: To provide a comprehensive review of daptomycin weight-based dosing methods for obese patients. Methods: PubMed, Embase, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched through December 31, 2022. Studies relevant to daptomycin weight-based dosing methods in obese adult patients were included. Results: Sixteen studies were included, of which five were case reports and 11 were cohort studies. Obese patients were included in all case reports, of which one was pregnant. The infections improved after receiving a daptomycin dose based on actual body weight (ABW) in all cases. Seven studies demonstrated that ABW, ideal body weight (IBW), and adjusted body weight (AjBW)-based daptomycin dosing differed in terms of treatment success, microbiological clearance, and creatinine phosphokinase (CPK) elevation. However, AjBW was not statistically equivalent to ABW in all evaluated outcomes, except for treatment success. Three studies showed a higher area under the concentration-time curve (AUC) by 60% in obese patients, whereas two studies indicated a higher maximum plasma concentration (Cmax) of ~2 folds. One study demonstrated that obese patients had higher levels of total clearance and volume of distribution, whereas other pharmacokinetic parameters were comparable between obese and non-obese patients. Conclusion: While most of the available evidence reported daptomycin dosing based on actual or total body weight, a few other studies have reported the use of ideal or adjusted body weight. A significant elevation in CPK was observed when daptomycin was administered based on AdjBW, but not with ABW and IBW. Further research is required to determine the optimal daptomycin weight-based dosing method in obese patients.
References
2. Fox AN, Smith WJ, Kupiec KE, et al. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight. Ther Adv Infect Dis. 2019;6:2049936118820230. https://doi.org/10.1177%2F2049936118820230
3. Payne KD, Hall RG 2nd. Dosing of antibacterial agents in obese adults: does one size fit all? Expert Rev Anti Infect Ther. 2014;12(7):829-54. https://doi.org/10.1586/14787210.2014.912942
4. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2007;27(8):1081-91. https://doi.org/10.1592/phco.27.8.1081
5. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
6. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. The American Journal of Clinical Nutrition. 1998;68(4):899-917. https://doi.org/10.1093/ajcn/68.4.899
7. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scandinavian Journal of Infectious Diseases. 2006;38(2):133-6. https://doi.org/10.1080/00365540500277292
8. Pai MP, Mercier RC, Allen SE. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Ann Pharmacother. 2006;40(3):553-8. https://doi.org/10.1345/aph.1g509
9. Pea F, Cojutti P, Sbrojavacca R, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011;45(7-8):e37. https://doi.org/10.1345/aph.1p745
10. Klibanov OM, Vickery S, Nortey C. Successful treatment of infective panniculitis with daptomycin in a pregnant, morbidly obese patient. Ann Pharmacother. 2014;48(5):652-5. https://doi.org/10.1177/1060028014523731
11. Cojutti PG, Carnelutti A, Mattelig S, et al. Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study. Ther Drug Monit. 2020;42(3):349-352. https://doi.org/10.1097/ftd.0000000000000740
12. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177-80. https://doi.org/10.1086/600039
13. Bookstaver PB, Bland CM, Qureshi ZP, et al. SERGE-45 Investigators. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy. 2013;33(12):1322-30. https://doi.org/10.1002/phar.1298
14. Ng JK, Schulz LT, Rose WE, et al. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother. 2014;58(1):88-93. https://doi.org/10.1128/aac.01018-13
15. Britt NS, Potter EM, Patel N, et al. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis. 2017;64(5):605-613. https://doi.org/10.1093/cid/ciw815
16. Lorenzo MP, Housman EL, Housman ST. Evaluation of Fixed-Dose Daptomycin in Obese Patients With Bloodstream Infections Caused by Staphylococcus aureus. Ann Pharmacother. 2020;54(3):290-291. https://doi.org/10.1177/1060028019883810
17. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. 2005;45(1):48-56. https://doi.org/10.1177/0091270004269562
18. Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51(8):2741-7. https://doi.org/10.1128/aac.00059-07
19. Butterfield-Cowper JM, Lodise TP Jr, Pai MP. A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults. Pharmacotherapy. 2018;38(9):981-985. https://doi.org/10.1002/phar.2157
20. Traunmüller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010;65(6):1252-7. https://doi.org/10.1093/jac/dkq109
21. Cubicin (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; February 2022.
22. Bhavnani SM, Rubino CM, Ambrose PG, et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568-74. https:// doi.org/10.1086/652767
23. Seaton RA, Menichetti F, Dalekos G, et al. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience Adv Ther. 2015;32(12):1192-205. https://doi.
.
org/10.1007/s12325-015-0267-4
24. Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin- resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(11):1568-76. https://doi.org/10.1093/cid/cit582
25. Ross JL, Rankin S, Marshik P, et al. Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin. Antibiotics (Basel). 2015;4(3):309-20. https://doi.org/10.3390/antibiotics4030309
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.